Regulatory Strategy & Submission Management Flashcards
9 cards from real CRAP practice questions. Tap to flip, then mark Knew It or Still Learning — missed cards come back until you master them.
Read the first 9 Regulatory Strategy & Submission Management flashcards as text
What is the main purpose of a regulatory strategy?
Answer: To ensure efficient approval and compliance
A regulatory strategy outlines the plan for navigating the complex regulatory landscape to bring a product to market. Its main purpose is to ensure that all necessary regulatory requirements are met efficiently, leading to timely approval while maintaining full compliance with relevant laws and guidelines. This minimizes risks and accelerates market access for new products.
Which agency approves drug submissions in the United States?
Answer: FDA
In the United States, the Food and Drug Administration (FDA) is the federal agency responsible for protecting public health by ensuring the safety, efficacy, and security of human and veterinary drugs, biological products, and medical devices. All new drug submissions must be approved by the FDA before they can be marketed and sold in the U.S.
What is a CTD?
Answer: Common Technical Document
The Common Technical Document (CTD) is a globally accepted format for organizing applications for new drugs and biologics. Developed by the International Council for Harmonisation (ICH), it standardizes the structure of regulatory submissions, making it easier for regulatory authorities worldwide to review and evaluate product information. This harmonization streamlines the approval process across different regions.
Why is early regulatory engagement important?
Answer: To align with expectations and avoid delays
Early regulatory engagement involves consulting with regulatory agencies during the initial stages of product development. This proactive approach helps developers understand agency expectations, identify potential regulatory hurdles, and align their development strategy accordingly. By addressing concerns early, companies can avoid costly delays and ensure a smoother, more efficient approval process.
What is an IND submission?
Answer: Investigational New Drug application
An Investigational New Drug (IND) application is a submission to the FDA that allows a pharmaceutical company to begin clinical trials in humans with a new drug. It provides comprehensive information on the drug's composition, manufacturing, and preclinical (animal) study results, demonstrating that it is reasonably safe for initial human testing. Without an approved IND, clinical trials cannot proceed.
Which region uses the EMA for drug regulation?
Answer: European Union
The European Medicines Agency (EMA) is responsible for the scientific evaluation, supervision, and safety monitoring of medicines in the European Union (EU) and European Economic Area (EEA). It plays a central role in the authorization of medicines across these member states, similar to the FDA in the United States. Its decisions impact market access for drugs throughout the region.
What does 'submission tracking' ensure?
Answer: Timely submission and regulatory updates
Submission tracking is a critical process in regulatory affairs that involves monitoring the status of applications and documents submitted to regulatory authorities. It ensures that submissions are made on time, deadlines are met, and any requests for additional information or updates from the agency are promptly addressed. This systematic approach helps maintain compliance and facilitates a smooth review process.
Which document supports drug safety during submissions?
Answer: Clinical study reports
Clinical study reports are comprehensive documents that detail the design, methodology, results, and analysis of human clinical trials. These reports provide crucial evidence of a drug's safety and efficacy, forming a cornerstone of regulatory submissions. Regulatory agencies rely heavily on these reports to assess the benefits and risks of a new medication before granting approval.
What does NDA stand for in regulatory submissions?
Answer: New Drug Application
A New Drug Application (NDA) is a formal submission to the FDA by a pharmaceutical company seeking approval to market a new drug in the United States. The NDA contains all the scientific data and information about the drug, including its safety, effectiveness, manufacturing, and labeling, gathered during preclinical and clinical development. Approval of an NDA signifies that the drug is safe and effective for its intended use.